Kornimate/medical-research-clean huggingface dataset:
self-administered acupressure for knee osteoarthritis: a pilot randomized controlled trial

Conditions: Knee Osteoarthritis

Summary: objectives: to test the feasibility of the study design and clinical effects of self-administered acupressure on relieving knee osteoarthritis (oa) pain. hypothesis: self-administered acupressure would have a superior beneficial effect compared to health education control group in terms of pain relief in patients with knee osteoarthritis across the 6-week study period. design and subjects: a pilot randomized controlled trial. 36 subjects with knee oa will be recruited; 18 per group. all eligible subjects will be randomized to either self-administered acupressure or health education control group in 1:1 ratio. interventions: subjects in the self-acupressure group will attend two 1.5 hours training sessions to learn self-acupressure and will practice self-acupressure every morning and night for 6 weeks; subjects in the education control group will receive two 1.5 hours training sessions to learn the health information related to knee oa. main outcome measures: the primary outcome measure is the numerical rating scale for knee pain. other measures include western ontario and mcmaster university osteoarthritis index, knees' range of motion (rom), and sf-6d. acceptability of the self-acupressure training course will also be evaluated. data analysis: differences in the questionnaire scores and rom will be examined using a mixed-effects model. both completer and intention-to-treat analyses will be conducted. effect sizes will be computed by dividing the difference in means by the pooled standard deviation.


Eligibility criteria:
inclusion criteria: * ethnic chinese; * aged 50 -70 years * fulfills any 3 of the following criteria proposed by altman et al., (1986): ( i. morning stiffness\</= 30 min; ii. crepitus on active joint motion; iii. bone tenderness; iv. bone enlargement; or v. no palpable joint warmth); * having knee pain for at least 3 months; * ability to provide informed consent; * ability to comprehend chinese; and * knee pain ≥3/10 and \</= 7 on a likert pain scale from 1-10 exclusion criteria: * medical diagnoses or conditions that preclude individuals from active participation (bleeding disorders, alcohol or drug abuse); * presence of skin lesions or infections at the treatment sites; * currently participating in other interventional research studies for knee oa; * cognitive impairment preventing informed consent or understanding of instructions * body mass index over 25, the obese criteria for asians (anuurad et al., 2003); * knee pain related to other conditions (cancer, fracture, rheumatoid arthritis, rheumatism) as screened according to the red flags for further investigation or referral in the nice 2014 guidelines for osteoarthritis of the knee; * had previous foot injury or trauma; * using of steroid for knee pain; * pregnancy or contemplating pregnancy; * ever received acupressure for knee oa over the past 6 months.

Keywords: knee osteoarthritis
obturator and femoral nerve block in patients with hip fracture

Conditions: Hip Fractures

Summary: a higher number than expected of patients with hip fracture have only insufficient analgesic effect of a femoral nerve block, which is the nerve block commonly used for this group of patients. one of the possible causes of this failure to provide analgesia from a single nerve block could be the that other nerves are involved in transmitting the pain signal. one of the nerves that is believed to give off branches to the hip is the obturator nerve. with ultrasound it is possible to make a selective proximal nerve block of the obturator nerve. the aim of this trial is to test the analgesic effect of a femoral nerve block i combination with an obturator nerve block compared to femoral nerve block alone in a randomized and placebo controlled design.

a higher number than expected of all patients with hip fracture have only insufficient analgesic effect of a femoral nerve block. one of the possible causes of this failure to provide analgesia from a single nerve block could be the that other nerves are involved in transmitting the pain signal. one of the nerves that is believed to give off branches to the hip is the obturator nerve. earlier it was believed that the so called '3-in-1-block' or the iliac fascia compartment block would anesthetize also the obturator nerve, and these two nerve blocks have been uses extensively in the emergency ward for preoperative analgesia. today that is not believed to be true and consequently is the part of the obturator nerve in patients with hip fracture unknown. with ultrasound it is possible to make a selective proximal nerve block of the obturator nerve before it branches into an anterior and a posterior branch. a selective nerve block of the obturator nerve to access its effect in patients with hip fracture has to our knowledge never been done. the aim of this trial is to test the analgesic effect of a femoral nerve block i combination with an obturator nerve block compared to femoral nerve block alone in a randomized and placebo controlled design.

Eligibility criteria:
inclusion criteria: * clinical suspicion of hip fracture * age ≥ 55 years * mentally capable of comprehending and using verbal pain score * mentally capable of differentiating between pain from the fractured hip and pain from other locations * mentally capable of understanding the given information * arrival in the emergency room at times when one of the doctors who do the nerve blocks for this investigation are on call * verbal numeric pain scale score (nrs 0-10) \> 5 with a dynamic test or nrs \> 3 at rest * patients informed consent exclusion criteria: * hip fracture not confirmed by x-ray * weight \< 40 kg * patient has previously been included in this trial * if the patient wishes to be excluded * allergy to local anesthetics or adrenocortical hormone * visible infection in the area of the point of needle injection
an observational study to evaluate the quality of life in korean female participants with chronic constipation

Conditions: Constipation

Summary: the purpose of this observational study is to investigate health related quality of life (qol) in korean female participants with chronic constipation (long term decreased number of or difficulty making bowel movements) having received treatment previously.

this is a cross-sectional (studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at 1 particular time) observational study (a scientific study to make a clear and easy understanding of the cause and effect relationship) to investigate the health related qol in korean female participants with chronic constipation having received treatment previously by using eq-5d (euroqol 5 dimension), sf-36 (short form health survey) and pac-qol (patient assessment of constipation) questionnaires. the duration of study will be 6 months. participant's safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: -korean female participants with chronic constipation having received treatment previously exclusion criteria: * male participants * participants with psychological disease (disorders of the mind, thoughts, and behavior)

Keywords: constipation prucalopride
study of cd200 activation receptor ligand (cd200ar-l) and allogeneic tumor lysate vaccine immunotherapy for recurrent glioblastoma

Conditions: Glioblastoma

Summary: this is a single-center, open-label, dose-range finding phase i study of hp1a8, a new adjuvant cd200 activation receptor ligand (cd200ar-l), in combination with imiquimod and the gbm6-ad vaccine to treat recurrent glioblastoma (gbm) in adults.


Eligibility criteria:
inclusion criteria: * aged 18 years and older. * confirmed diagnosis of gbm. * radiographically or histologically proven progression or recurrence of disease at any time after standard of care therapy (radiation, temozolomide, with or without a tumor treatment field device). * tumor debulking or biopsies may be performed to clinical trial enrollment if indicated and feasible. exclusion criteria: * bevacizumab or targeted therapy within 45 days of enrollment. * intercurrent immune system disorder such as hypoimmunity (marrow failure, hiv) or hyperimmunity (autoimmune disease). * unable to complete a standard upfront course of chemoradiotherapy due to disease progression or intolerance of therapy. * history of gliadel water, gammatile or other implanted therapeutic agent. * concurrent use of tumor treatment field devices (e.g. optune).
pet/mri in the diagnosis of chronic pain

Conditions: Neuropathic Pain; Nociceptive Pain; Mixed Pain (Nociceptive and Neuropathic); Spinal Pain; Radiculopathy; Myelopathy; Neurogenic Claudication

Summary: several studies have implicated involvement of sigma-1 receptors (sr1s) in the generation of chronic pain, while others are investigating anti sr1 drugs for treatment of chronic pain. using \[18f\]-ftc-146 and positron emission tomography/magnetic resonance imaging (pet/mri), the investigators hope to identify the source of pain generation in patients with chronic pain. the purpose of this study is to compare the uptake of \[18f\]ftc-146 in healthy volunteers to that of individuals suffering from chronic pain.

chronic pain is a significant, widespread problem affecting every fifth person worldwide. reported in 2011 by the institute of medicine, chronic pain affects 116 million american adults - more than the total number of individuals affected by heart disease, cancer, and diabetes combined. an estimated $635 billion each year is spent in the medical management of chronic pain and lost productivity. better clinical methods to diagnose and localize pain are needed. the investigators have developed a s1r-specific radiotracer, \[18f\]ftc-146. using imaging approaches to assess the location of s1r in pain may provide a tool to diagnose pain generators, monitor treatment response, and aid in the selection of patients for treatment. the goal is to use \[18f\]ftc-146 to image s1r expression in healthy volunteers and to compare the images to those individuals suffering from pain conditions in the following categories: (1) nociceptive pain (pain that results from tissue injury or inflammation), (2) neuropathic pain (pain that results from direct injury, disruption, impingement/compression or malfunction of the peripheral and/or central nervous system), and (3) mixed pain (pain that appears to have both nociceptive and neuropathic).

Eligibility criteria:
inclusion criteria: healthy volunteers: 1. at least 18 years old. 2. covid vaccination status: vaccinated or unvaccinated subjects who received a negative test result from the covid test within 72 hours of the scan. pain patients: 1. at least 18 years old. 2. chronic pain (nociceptive, neuropathic or mixed pain) lasting greater than 2 months. 3. pain level of at least 4/10 on a 0-10 comparative pain scale. 4. covid vaccination status: vaccinated or unvaccinated subjects who received a negative test result from the covid test within 72 hours of the scan. exclusion criteria: healthy volunteers: 1. pain 2. pain medication 3. mri incompatible 4. pregnant or nursing 5. non-english speaker 6. claustrophobic pain patients: 1. mri incompatible 2. pregnant or nursing 3. non-english speaker 4. claustrophobic

Keywords: pet/mri chronic pain
pelvic girdle pain symptom severity in pregnant women with gestational diabetes mellitus

Conditions: Pregnant Women; Gestational Diabetes; Pelvic Girdle Pain

Summary: pelvic girdle pain (pgp), which is a common musculoskeletal problem of pregnancy, and gestational diabetes mellitus (gdm), which is diagnosed at the end of the second trimester and at the beginning of the third trimester, occur in a parallel time period. the addition of hyperglycemia to the physiological changes in pregnancy stimulates a new series of cycles and contributes to inflammation, and it is predicted that the presence of gdm may trigger the pain intensity of pgp. therefore, the aim of this study is to investigate the effect of gdm on pgp symptom severity (pain).


Eligibility criteria:
inclusion criteria: * pregnant women (with pgp) diagnosed with gdm in the 2nd and 3rd trimesters, whose treatment process (diet/insulin) for insulin regulation have been started. * pregnant women (with pgp) diagnosed with gdm in the 2nd and 3rd trimesters, whose treatment process (diet/insulin) for insulin regulation have not been started * pregnant women (with pgp) who were not diagnosed with gdm in the 2nd and 3rd trimesters exclusion criteria: * pre-pregnancy diabetes mellitus * presence of an orthopedic or neurological problem that may cause musculoskeletal disorders and deviations from normal biomechanical alignment * presence of connective tissue disease * definition of chronic low back-pelvic region pain (lasting for more than 3 months and pain severity \>4 according to vas) before pregnancy * history of spine, pelvis, or lower extremity surgery or fracture in the past 6 months * history of pelvic fracture

Keywords: pregnant women pelvic girdle pain gestational diabetes
prevalence of parental burnout among mothers of children with cerebral palsy

Conditions: Parents; Burnout; Children, Only; Cerebral Palsy

Summary: this study will be done to determine the prevalence of parental burnout among mothers of children with cerebral palsy. determine the relation between parental burnout syndrome and the motor function levels of children with cerebral palsy.

cerebral palsy is a significant physical disability in children, affecting 2-5 children per 1,000 live births globally. the prevalence varies between countries and is higher in low- and middle-income countries. studies suggest a relationship between children's motor impairment and parental stress, which can lead to illness, negative family dynamics, and neglect. parenting stress and pressure have increased, leading to exhaustion and burnout among parents. this study aims to investigate the prevalence of parental bowel syndrome among mothers of children with cp and its relation to motor function levels.

Eligibility criteria:
inclusion criteria: * mothers of children with cp of any age. * children diagnosed with cp. * the age of children will range from 3-18 years old. exclusion criteria: * mothers who refuse to participate in the study. * mothers of more than one disabled child.
short-term survival in patients with severe alcoholic hepatitis treated with steroid versus pentoxifylline

Conditions: Alcoholic Hepatitis

Summary: alcoholic hepatitis represents one of the more serious forms of alcoholic liver disease. critically ill patients with alcoholic hepatitis have high morbidity and mortality rate. because of data suggesting that the pathogenic mechanisms in alcoholic hepatitis involve cytokine release and the perpetuation of injury by immunologic process, corticosteroid has been extensively evaluated in the treatment of alcoholic hepatitis. although there are discrepancies in literature as several randomized trials and meta-analyses have reached contradictory results, corticosteroid for a subset of patients with severe alcoholic hepatitis, defined as a discriminant function ≥ 32, who also have no concomitant gastrointestinal bleeding, active infection, renal failure, and pancreatitis, has been recommended. this latter point emphasizes the important of meticulous selection to avoid the side effects of corticosteroid. thus, the beneficial effects seems confined to a highly selected minority group in which the inhibitory effect of corticosteroid on liver inflammation is not outweighed by side effects such as weakened defense against infection, anti-anabolic effects, and possible ulcer-promoting effects causing gastrointestinal bleeding, which may be deleterious in these critically ill patients. newer understanding of the role of the role of tnf-α expression and receptor activity in alcoholic liver injury has prompted to an examination of tnf inhibition as an alternative to corticosteroid for severe alcoholic hepatitis. pentoxifylline, a nonspecific tnf inhibitor, recently has been demonstrated in a randomized trial to improve survival in the therapy of severe alcoholic hepatitis. in particular, the survival benefit of pentoxifylline appears to be related to a significant reduction in development of hepatorenal syndrome. these results are promising, and support the need to further evaluate the potential of this new therapeutic avenue. there is a need for head to head comparison of corticosteroid and pentoxifylline in severe alcoholic hepatitis. at the time the current study was designed (2008), corticosteroid was first-line treatment for severe alcoholic hepatitis. this study was designed to demonstrate that the effect of pentoxifylline was similar (i.e., not inferior) to that of prednisolone, an active form of prednisone. the aim of the present study was thus to compare the effects of pentoxifylline and prednisolone on the short-term mortality.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of severe alcoholic hepatitis (discriminant function ≥ 32 points), must be able to swallow tablets. exclusion criteria: * gastrointestinal bleeding bacterial infection hbsag positivity acute pancreatitis

Keywords: severe alcoholic hepatitis
use of activated recombinant fvii in spinal surgery

Conditions: Acquired Bleeding Disorder; Spinal Fusion

Summary: this trial is conducted in the united states of america (usa). the purpose of this clinical research trial is to understand how safe and effective recombinant activated fvii is for reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.


Eligibility criteria:
inclusion criteria: * elective spinal fusion surgery. exclusion criteria: * history of thrombotic disorders (myocardial infarction, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation or peripheral artery thrombosis) * any trauma within the last 3 months leading to hospitalization \> 24 hours * angina or known coronary artery disease
digital secondary prevention in cardiovascular disease

Conditions: Atherosclerotic Plaque

Summary: although advances in knowledge of the prevention, diagnosis and treatment of atherothrombosis are encouraging, cardiovascular diseases (cvd), with acute and chronic ischemic heart disease in particular, remain a major cause of disability and premature death throughout the world. cardiac rehabilitation (cr) and secondary prevention are coordinated multidimensional evidence-based strategies that aim to assist patients with acute and chronic ischemic heart disease return to an active and satisfying life and to prevent the recurrence of further cardiac events. since cr is time limited after an acute event, secondary prevention proposes a continuum where care is provided for the rest of a person's life according to the existence of cardiovascular risk factors. secondary prophylaxis is fundamental for the recovery of the patient, but in most cases, it is only insufficiently implemented. to ensure adequate resources for the delivery of health care and to further improve the level of care, care-delivery models need to be changed in a way that patients themselves become more involved in their own care. mobile health (mhealth) is a rapidly growing health delivery methodology with the potential to impact on health care research, health care delivery and health outcomes. therefore, the aim of the study is to determine the impact of plaque visualization using a digital intervention on treatment adherence to improve the cardiovascular risk profile. participants will be randomized into two groups: intervention group and control group. participants of the control group receive the best medical care according to current guideline recommendations without access to the app. participants of the intervention group receive the best medical care according to current guideline recommendations with full access to the smartphone application at time of study begin until the completion of the follow-up period of 12 months. the access to the app includes access to relevant findings including ultrasound images of the carotid artery, lipid profile, blood pressure values, and weight.


Eligibility criteria:
inclusion criteria: * ultrasound evidence of atherosclerotic plaque in one or both carotid arteries * own a smartphone and know how to use apps * presumed life expectancy of more than one year * willing to comply with the protocol and provide written informed consent exclusion criteria: * congestive heart failure with nyha (new york heart association classification) iii-iv symptoms * severe valve disease * no german knowledge * unwillingness to user the app and/or undergo diagnostic procedures
aza-ven followed by reduced toxicity conditioning regimen (mbf) as salvage therapy for refractory aml.

Conditions: Refractory Acute Myeloid Leukemia

Summary: in this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen consisting of fludarabine + busulfan + melphalan as salvage treatment in patients with refractory aml .

in refractory aml, allogeneic hematopoietic stem cell transplantation (allo-hcst) is considered as the only curative regimen. in this phase ii clinical trial, we plan to evaluate the efficacy and feasibility of new sequential transplantation protocol. all patients receive azacytidine and venetoclax as leukemia debulking treatment which is followed by reduced intensity conditioning regimen consisting of fludarabine (150mg/m2) + busulfan (6.4mg/kg) + melphalan (70mg/m2). the graft-versus host disease (gvhd) prophylaxis regimen is based on reduced dose of post-transplantation cyclophosphamide (pt-cy) 40mg/kg day+3\~+4, tacrolimus and low-dose anti-thymoglobulin (atg, 2.5mg/kg) in case of hla-matched unrelated donor or halo-donor transplantation.

Eligibility criteria:
inclusion criteria: * refractory aml (no remission after 2 induction therapy, relapsed aml within 6 months of first complete remission (cr), relapse aml no cr after reinduction therapy), multiple relapse and refractory relapse aml * patients with hla matched related or unrelated donor (9\~10/10) or haplo-identical related donor exclusion criteria: * patients with poor liver function (enzyme \>2n or bilirubin \>2n) * poor renal function (scr \>1.5n) * poor cardiac function （ef\<45%） * inform consent not provided

Keywords: refractory acute myeloid leukemia hematopoietic stem cell transplantation